In the News

Find articles and press on AgeneBio and research updates regarding hippocampal overactivity and aMCI.

September 14, 2016

Doctors Discuss Alzheimer’s Advancements

NJTV News

Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, was interviewed by NJTV News during the 17th International Conference on Alzheimer’s Drug Discovery, sponsored by the Alzheimer’s Drug Discovery Foundation.

December 21, 2015

The faces of Alzheimer’s Part IV: Face of the researcher and the future

Pine Journal

Promising early research by John Hopkins University and startup drug company AgeneBio successfully showed low dose treatment of AGB101 to lab animals, like rats, resulted in calmed over-activity in the brain and improved memory performance in subjects experiencing memory loss…

December 8, 2015

Baltimore biopharm hires neuroscience veteran Mohs as VP

The Daily Record

Baltimore-based biopharmaceutical company AgeneBio has appointed Richard Mohs as vice president of clinical development. Mohs has more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab…

November 25, 2015

From Truly New to Déjà Vu: Investigational Therapy News at CTAD

ALZFORUM

n the last session of CTAD, Michela Gallagher of Johns Hopkins University, Baltimore, fired up a tired audience with news that a proprietary low-dose formulation of the atypical antiepileptic drug levetiracetam, called AGB101, was set to start a Phase 3…

November 18, 2015

Slow Down

Johns Hopkins University Arts & Sciences Magazine

Could decelerating an overactive hippocampus halt Alzheimer’s disease in its tracks? Neuroscientist Michela Gallagher and her colleagues across the university aim to find out.

September 24, 2015

Potential Alzheimer’s drug gets funding for clinical testing

Bend Bulletin

What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the…

September 21, 2015

New Alzheimer Trial Will Use Epilepsy Drug

Lawton Constitution

What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the…

September 20, 2015

Drug for Early Alzheimer’s Heads to Clinical Trial

Imperial Valley News

Johns Hopkins University researchers have received an estimated $7.5 million National Institutes of Health grant to clinically test what would be the first treatment to prevent or delay the onset of Alzheimer’s dementia.